Oral Mesoporous Silica Nanoparticles for Delaying Diabetes Progression in Adults With Prediabetes and Obesity

Article Sidebar

Full Text PDF
Published: 2026-03-15
DOI: https://doi.org/10.61919/abmz4872
Keywords:
Blood Glucose; Glycated Hemoglobin; Mesoporous Silica Nanoparticles; Obesity; Prediabetes; Randomized Controlled Trial; Silicon Dioxide.

Main Article Content

Mukhtar Ullah
MPhil Pharmaceutics, Kohat University of Science and Technology, Kohat, Pakistan
Fatima Tariq
Medical Officer, Yameen Medical and Surgical Center, Samundri, Pakistan
Maham Khalil
Research Associate, Ziauddin University, Karachi, Pakistan
Baldev Kumar
Medical Officer, Basic Health Unit Sargesha, Dalbandin, Pakistan
Muhammad Abbas Sadiq
Relizon Pharmaceuticals, Lahore, Pakistan
Maryam Shehzadi
PharmD, The University of Faisalabad, Faisalabad, Pakistan
Muhammad Farman
University of Okara, Okara, Pakistan

Abstract

Background: Prediabetes and obesity increase the risk of type 2 diabetes. Oral mesoporous silica nanoparticles (SiPore21) may influence gastrointestinal nutrient digestion and glycemic regulation. Objective: To evaluate the efficacy and short-term tolerability of oral SiPore21 gel in adults with prediabetes and obesity. Methods: A 12-week, double-blind, placebo-controlled randomized trial was conducted in urban Sindh, Pakistan, between June 2025 and January 2026. Eighty adults were randomized equally to SiPore21 gel (3 g three times daily) or matched placebo. Seventy-four participants completed follow-up and were included in complete-case analyses. Primary outcomes were changes in glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG). Secondary outcomes included body composition, lipid parameters, and two-hour glucose. Between-group changes were compared using independent-samples t-tests. Results: HbA1c decreased by 0.31 ± 0.18 percentage points with SiPore21 versus 0.03 ± 0.19 with placebo. The between-group difference in change was −0.28 percentage points (95% CI: −0.37 to −0.19; p < 0.001). FPG changes differed by −9.00 mg/dL (95% CI: −11.55 to −6.45; p < 0.001). Secondary metabolic differences favored SiPore21. Mild gastrointestinal adverse events occurred in four intervention and three placebo participants; no severe events were reported. Conclusion: SiPore21 was associated with favorable short-term glycemic outcomes, but longer-term effectiveness, safety, and diabetes prevention remain unestablished.

Article Details

Issue

Vol. 4 No. 5 (2026)

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Mukhtar Ullah et al. 2026. Oral Mesoporous Silica Nanoparticles for Delaying Diabetes Progression in Adults With Prediabetes and Obesity. Journal of Health, Wellness and Community Research. 4, 5 (Mar. 2026), 1–10. DOI:https://doi.org/10.61919/abmz4872.

References

1. Roy R, Chakraborty A, Jana K, Sarkar B, Biswas P, Madhu NR. The broader aspects of treating diabetes with the application of nanobiotechnology. InAdvances in Diabetes Research and Management 2023 Mar 10 (pp. 137-162). Singapore: Springer Nature Singapore.

2. Castellano JM, Ramos-Romero S, Perona JS. Oleanolic acid: extraction, characterization and biological activity. Nutrients. 2022 Jan 31;14(3):623.

3. Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. International Journal of Biological Sciences. 2023 Jan 1;19(1):66.

4. Abbasi M, Heath B, McGinness L. Advances in metformin‐delivery systems for diabetes and obesity management. Diabetes, Obesity and Metabolism. 2024 Sep;26(9):3513-29.

5. Kamran SH. Nanomedicine in the Treatment of Metabolic Diseases. InNanomedicine in Treatment of Diseases 2024 Jan 28 (pp. 213-255). Singapore: Springer Nature Singapore.

6. Stoleru OA, Burlec AF, Mircea C, Felea MG, Macovei I, Hăncianu M, Corciovă A. Multiple nanotechnological approaches using natural compounds for diabetes management. Journal of Diabetes & Metabolic Disorders. 2024 Jun;23(1):267-87.

7. Sarkar S, Ekbal Kabir M, Kalita J, Manna P. Mesoporous silica nanoparticles: drug delivery vehicles for antidiabetic molecules. ChemBioChem. 2023 Apr 3;24(7):e202200672.

8. Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y, Jin Y. Research progress on peptide drugs for type 2 diabetes and the possibility of oral administration. Pharmaceutics. 2024 Oct 23;16(11):1353.

9. Tuccinardi D, Masi D, Watanabe M, Zanghi Buffi V, De Domenico F, Berti S, Cipriani V, Manco M, Manfrini S, Pagotto U. Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. Journal of Endocrinological Investigation. 2025 Dec;48(12):2761-98.

10. Ayub H, Islam M, Saeed M, Ahmad H, Al‐Asmari F, Ramadan MF, Alissa M, Arif MA, Rana MU, Subtain M, Rahim MA. On the health effects of curcumin and its derivatives. Food Science & Nutrition. 2024 Nov;12(11):8623-50.

11. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology. 2023 Apr 21;14:1161521.

12. Islam MS, Sharif A, Kwan N, Tam KC. Bile acid sequestrants for hypercholesterolemia treatment using sustainable biopolymers: Recent advances and future perspectives. Molecular Pharmaceutics. 2022 Mar 25;19(5):1248-72.

13. Zahkouk SA, Eid FA, Abdelhafez HM, El-Wahsh AM. Effect of Aphanizomenon flos-aquae (AFA) or Orlistat on hyperlipidemic adult male Albino rats. Journal of Medical and Life Science. 2019 Dec 1;1(4):83-103.

14. Guan HP, Xiong Y. Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders. Frontiers in pharmacology. 2022 Oct 25;13:1043828.

15. Subramaniyan V, Hanim YU. Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions. International Journal of Obesity (2005). 2025 Feb 27;49(3):492.

16. Guyton JR. Lipoproteins in Diabetes: Risk and Opportunity. InType 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management 2008 (pp. 265-288). Totowa, NJ: Humana Press.